Viagenpumatucel-L

DB16348InvestigationalVaccines

Viagenpumatucel-L is under investigation in clinical trial NCT02117024 (A Phase 2 Study of Viagenpumatucel-l (HS-110) in Patients With Non-small Cell Lung Cancer).

Mechanism: Pharmacologically active on Endoplasmin
Curator reviewed
Also known as: Gp96-igg1-fc fusion protein and hla-a1 expressing, irradiated ad-100 whole cell vaccine · Viagenpumatucel l
Code names: HS-110

Resolves to

Compound

UNII13H90KC831

Targets

P14625HSP90B1

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Viagenpumatucel-L, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account